Encarna Domenech-Campos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Encarna Domenech-Campos has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ainhoa García-Lliberós
Rhinology Unit, Hospital General Universitario, 46014 Valencia, Spain
2 shared publications - Alfonso García-Piñero
Department of Otorhinolaryngology, Hospital Universitari i Politècnic La Fe, 46026 Valencia, Spain
2 shared publications - Carlos Zac-Romero
Pathology Department, HUiP La Fe, 46026 Valencia, Spain
2 shared publications - Carmen García-Navalón
Rhinology Unit, Hospital General Universitario, 46014 Valencia, Spain
2 shared publications - Cecilia López-Valdivia
Pathology Department, HUiP La Fe, 46026 Valencia, Spain
2 shared publications - Chakib Taleb
Rhinology Unit, Hospital Clínico Universitario, 46010 Valencia, Spain
2 shared publications
Latest Publications
- Open Access
- 24 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5248
Transforming Patient Experience: Real-World Impact of Mepolizumab on Symptom Burden in Chronic Rhinosinusitis with Nasal Polyps—A Multicenter Perspective
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic upper airway disease that may involve different inflammatory endotypes, although in Western populations it is most commonly associated with type 2 inflammation. CRSwNP has a significant impact on the patient’s quality of life. The recommended appropriate medical therapy is effective in controlling CRSwNP symptoms in many patients; however, a subset continues to exhibit persistent type 2 inflammation, evidenced by recurrent nasal polyps, elevated eosinophil counts, or the need for systemic corticosteroids or surgery. Monoclonal antibodies have recently become a novel and personalized treatment that can help refractory patients restore disease control. Objective: The present study aims to evaluate the effectiveness of mepolizumab in real-world settings in a diverse patient population, focusing on assessing the impact of this therapy on patient-reported outcomes after six months of treatment. Methods: This is a multicenter, observational study of CRSwNP patients treated with mepolizumab carried out in five hospitals located in Spain. Adult patients with a diagnosis of uncontrolled CRSwNP were included in the study. The change in the nasal polyp score (NPS) was the main clinical endpoint. Changes in the Sinonasal Outcome Test (SNOT-22), nasal congestion and smell impairment visual analogue scale scores, and blood and nasal polyp tissue eosinophil counts were among other endpoints included. Results: In total, 47 patients were included, and 91% were asthmatic. The nasal polyp score (0–8) was reduced significantly in the cohort (mean change: −2.56, p < 0.0001). The mean SNOT-22 score improved 25.29 points. Nasal congestion (−3.57, p < 0.0001) and smell impairment (−4.0, p < 0.0001) visual analog scale scores (0–10) showed a significant improvement. Blood and tissue eosinophil median counts showed significant reductions versus baseline of 86% and 26%, respectively. Among those patients with asthma, the asthma control test score achieved a median value of 24 points. Conclusions: This study provides real-world evidence supporting the effectiveness of mepolizumab in managing CRSwNP in patients with features suggestive of type 2 inflammation. The observed improvements in patient-reported outcomes, nasal polyp burden, and asthma control suggest that mepolizumab may be a valuable therapeutic option for this patient population.
- 24 July 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (15) , 5248
Open AccessTransforming Patient Experience: Real-World Impact of Mepolizumab on Symptom Burden in Chronic Rhinosinusitis with Nasal Polyps—A Multicenter Perspective
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic upper airway disease that may involve different inflammatory endotypes, although in Western populations it is most commonly associated with type 2 inflammation. CRSwNP has a significant impact on the patient’s quality of life. The recommended appropriate medical therapy is effective in controlling CRSwNP symptoms in many patients; however, a subset continues to exhibit persistent type 2 inflammation, evidenced by recurrent nasal polyps, elevated eosinophil counts, or the need for systemic corticosteroids or surgery. Monoclonal antibodies have recently become a novel and personalized treatment that can help refractory patients restore disease control. Objective: The present study aims to evaluate the effectiveness of mepolizumab in real-world settings in a diverse patient population, focusing on assessing the impact of this therapy on patient-reported outcomes after six months of treatment. Methods: This is a multicenter, observational study of CRSwNP patients treated with mepolizumab carried out in five hospitals located in Spain. Adult patients with a diagnosis of uncontrolled CRSwNP were included in the study. The change in the nasal polyp score (NPS) was the main clinical endpoint. Changes in the Sinonasal Outcome Test (SNOT-22), nasal congestion and smell impairment visual analogue scale scores, and blood and nasal polyp tissue eosinophil counts were among other endpoints included. Results: In total, 47 patients were included, and 91% were asthmatic. The nasal polyp score (0–8) was reduced significantly in the cohort (mean change: −2.56, p < 0.0001). The mean SNOT-22 score improved 25.29 points. Nasal congestion (−3.57, p < 0.0001) and smell impairment (−4.0, p < 0.0001) visual analog scale scores (0–10) showed a significant improvement. Blood and tissue eosinophil median counts showed significant reductions versus baseline of 86% and 26%, respectively. Among those patients with asthma, the asthma control test score achieved a median value of 24 points. Conclusions: This study provides real-world evidence supporting the effectiveness of mepolizumab in managing CRSwNP in patients with features suggestive of type 2 inflammation. The observed improvements in patient-reported outcomes, nasal polyp burden, and asthma control suggest that mepolizumab may be a valuable therapeutic option for this patient population.
- Open Access
- 21 May 2025
- Published by MDPI AG in Preprints.org
Transforming Patient Experience: Real-World Impact of Mepolizumab on Symptom Burden in Chronic Rhinosinusitis with Nasal Polyps—A Multicenter Perspective
Background: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a type-2 inflammatory upper respiratory disease that has a significant impact on the patient's quality of life. The recommended appropriate medical therapy is effective in controlling CRSwNP symptoms, but some patients are unable to control inflammation. Monoclonal antibodies have recently become a novel and personalized treatment that can help refractory patients restore disease control. Objective: The present study aims to evaluate the effectiveness of mepolizumab in real life settings in a diverse patient population, focusing on assessing the impact of this therapy on patient reported outcomes after six months of treatment. Methods: This is a multicenter, observational study of CRSwNP patients treated with mepolizumab carried out in five hospitals located in Spain. Adult patients with a diagnosis of uncontrolled CRSwNP were included in the study. The change in nasal polyp score (NPS) was the main clinical endpoint. Changes in Sinonasal Outcome Test (SNOT-22), nasal congestion and smell impairment visual analogical scales and blood and nasal polyp tissue eosinophil counts were among other endpoints included. Results: 47 patients were included. 91% were asthmatic. The nasal polyp score (0-8) was reduced significantly in the cohort (mean change: -2.56, p 0.0001). Mean SNOT-22 score improved 25.29 points. Nasal congestion (-3.57, p<0.0001) and smell impairment (-4.0, p<0.0001) visual analogical scales (0 -10) showed a significant improvement. Blood and tissue eosinophil median counts showed a significant reduction versus baseline of 86% and 26% respectively. Among those patients with asthma, the asthma control test score achieved a median value of 24 points. Conclusion: This study provides compelling evidence for the effectiveness of mepolizumab in managing recalcitrant CRSwNP in a real-world setting.
- 21 May 2025
- Published by MDPI AG in Preprints.org
Open AccessTransforming Patient Experience: Real-World Impact of Mepolizumab on Symptom Burden in Chronic Rhinosinusitis with Nasal Polyps—A Multicenter Perspective
Background: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a type-2 inflammatory upper respiratory disease that has a significant impact on the patient's quality of life. The recommended appropriate medical therapy is effective in controlling CRSwNP symptoms, but some patients are unable to control inflammation. Monoclonal antibodies have recently become a novel and personalized treatment that can help refractory patients restore disease control. Objective: The present study aims to evaluate the effectiveness of mepolizumab in real life settings in a diverse patient population, focusing on assessing the impact of this therapy on patient reported outcomes after six months of treatment. Methods: This is a multicenter, observational study of CRSwNP patients treated with mepolizumab carried out in five hospitals located in Spain. Adult patients with a diagnosis of uncontrolled CRSwNP were included in the study. The change in nasal polyp score (NPS) was the main clinical endpoint. Changes in Sinonasal Outcome Test (SNOT-22), nasal congestion and smell impairment visual analogical scales and blood and nasal polyp tissue eosinophil counts were among other endpoints included. Results: 47 patients were included. 91% were asthmatic. The nasal polyp score (0-8) was reduced significantly in the cohort (mean change: -2.56, p 0.0001). Mean SNOT-22 score improved 25.29 points. Nasal congestion (-3.57, p<0.0001) and smell impairment (-4.0, p<0.0001) visual analogical scales (0 -10) showed a significant improvement. Blood and tissue eosinophil median counts showed a significant reduction versus baseline of 86% and 26% respectively. Among those patients with asthma, the asthma control test score achieved a median value of 24 points. Conclusion: This study provides compelling evidence for the effectiveness of mepolizumab in managing recalcitrant CRSwNP in a real-world setting.